首页> 外文期刊>Cell metabolism >Human Brown Adipocyte Thermogenesis Is Driven by beta 2-AR Stimulation
【24h】

Human Brown Adipocyte Thermogenesis Is Driven by beta 2-AR Stimulation

机译:人棕色脂肪细胞热生成由β2-AR刺激驱动

获取原文
获取原文并翻译 | 示例
           

摘要

Stimulation of brown adipose tissue (BAT) thermogenesis in humans has emerged as an attractive target to improve metabolic health. Pharmacological stimulations targeting the beta(3)-adrenergic receptor (beta(3)-AR), the adrenergic receptor believed to mediate BAT thermogenesis, have historically performed poorly in human clinical trials. Here we report that, in contrast to rodents, human BAT thermogenesis is not mediated by the stimulation of beta(3)-AR. Oral administration of the beta(3)-AR agonist mirabegron only elicited increases in BAT thermogenesis when ingested at the maximal allowable dose. This led to off-target binding to beta(1)-AR and beta(2)-AR, thereby increasing cardiovascular responses and white adipose tissue lipolysis, respectively. ADRB2 was co-expressed with UCP1 in human brown adipocytes. Pharmacological stimulation and inhibition of the beta(2)-AR as well as knockdown of ADRB1, ADRB2, or ADRB3 in human brown adipocytes all confirmed that BAT lipolysis and thermogenesis occur through beta(2)-AR signaling in humans (ClinicalTrials.gov NCT02811289).
机译:刺激人类棕色脂肪组织(BAT)热生成被出现为改善代谢健康的有吸引力的靶标。靶向β(3) - 肾上腺素能受体(β(3)-AR)的药理学刺激,肾上腺素能受体认为介导蝙蝠热生成,在人类临床试验中历史较差。在这里,我们报告说,与啮齿动物相比,人蝙蝠热生成未被β(3)-AR的刺激介导。口服β(3)-AR激动剂M拉释的施用仅在最大允许剂量摄入时仅引发蝙蝠热量的增加。这导致β(1)-AR和β(2)-AR的脱靶结合,从而增加心血管反应和白色脂肪组织脂肪解。 ADRB2用UCP1与人棕色脂肪细胞共同表达。药理刺激和β(2)-AR的抑制以及人棕色脂肪细胞中AdRB1,AdRB2或AdRB3的敲低均证实了通过人类的β(2)-AR信号传导发生蝙蝠脂解和热生成(ClinicalTrial.gov NCT02811289 )。

著录项

  • 来源
    《Cell metabolism》 |2020年第2期|共21页
  • 作者单位

    Ctr Hosp Univ Sherbrooke Ctr Rech Sherbrooke PQ Canada;

    Univ Copenhagen Fac Hlth &

    Med Sci Novo Nordisk Fdn Ctr Basic Metab Res Copenhagen Denmark;

    Leiden Univ Med Ctr Div Endocrinol Dept Med Leiden Netherlands;

    Univ Copenhagen Fac Hlth &

    Med Sci Novo Nordisk Fdn Ctr Basic Metab Res Copenhagen Denmark;

    Univ Copenhagen Fac Hlth &

    Med Sci Novo Nordisk Fdn Ctr Basic Metab Res Copenhagen Denmark;

    Univ Laval Fac Pharm Ctr Rech Inst Univ Cardiol &

    Pneumol Quebec Quebec City PQ Canada;

    Univ Copenhagen Fac Hlth &

    Med Sci Novo Nordisk Fdn Ctr Basic Metab Res Copenhagen Denmark;

    Leiden Univ Med Ctr Div Endocrinol Dept Med Leiden Netherlands;

    Leiden Univ Med Ctr Div Endocrinol Dept Med Leiden Netherlands;

    Ctr Hosp Univ Sherbrooke Ctr Rech Sherbrooke PQ Canada;

    Ctr Hosp Univ Sherbrooke Ctr Rech Sherbrooke PQ Canada;

    Ctr Hosp Univ Sherbrooke Ctr Rech Sherbrooke PQ Canada;

    Univ Sherbrooke Ctr Imagerie Mol Sherbrooke Dept Nucl Med &

    Radiobiol Sherbrooke PQ Canada;

    Univ Sherbrooke Ctr Imagerie Mol Sherbrooke Dept Nucl Med &

    Radiobiol Sherbrooke PQ Canada;

    Univ Ottawa Fac Hlth Sci Ottawa ON Canada;

    Univ Laval Fac Pharm Ctr Rech Inst Univ Cardiol &

    Pneumol Quebec Quebec City PQ Canada;

    Univ Laval Fac Pharm Ctr Rech Inst Univ Cardiol &

    Pneumol Quebec Quebec City PQ Canada;

    Leiden Univ Med Ctr Div Endocrinol Dept Med Leiden Netherlands;

    Univ Copenhagen Fac Hlth &

    Med Sci Novo Nordisk Fdn Ctr Basic Metab Res Copenhagen Denmark;

    Univ Sherbrooke Dept Med Sherbrooke PQ Canada;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内分泌腺疾病及代谢病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号